ATC Group: M09AX07 Nusinersen

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M09AX07 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M09 Other drugs for disorders of the musculo-skeletal system
3 M09A Other drugs for disorders of the musculo-skeletal system
4 M09AX Other drugs for disorders of the musculo-skeletal system
5 M09AX07

Active ingredients in M09AX07

Active Ingredient Description
Nusinersen

Nusinersen is an antisense oligonucleotide (ASO) which increases the proportion of exon 7 inclusion in survival motor neuron 2 (SMN2) messenger ribonucleic acid (mRNA) transcripts by binding to an intronic splice silencing site (ISS-N1) found in intron 7 of the SMN2 pre-messenger ribonucleic acid (pre-mRNA) and hence when SMN2 mRNA is produced, it can be translated into the functional full length SMN protein. SMA is a progressive neuromuscular disease resulting from mutations in chromosome 5q in the SMN1 gene. Gene SMN2, located near SMN1, is responsible for a small amount of SMN protein production.

Related product monographs

Title Information Source Document Type  
SPINRAZA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.